✦ LIBER ✦

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

✍ Scribed by Anthony L. Zietman; Katherine C. Dallow; Patricia A. McManus; Niall M. Heney; William U. Shipley

Book ID: 119488069
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 422 KB
Volume: 47
Category: Article
ISSN: 0090-4295
DOI: 10.1016/s0090-4295(99)80423-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1013 Time to second prostate specific an

1013 Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease

✍ A.L. Zietman; K.C. Dallow; W.U. Shipley; N.M. Haney; P.L. McManus 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Prospective Preference Assessment of Pat

Prospective Preference Assessment of Patients' Willingness to Participate in a Randomized Controlled Trial of Intensity Modulated Radiotherapy versus Proton Therapy for Localized Prostate Cancer

✍ A. Shah; J.A. Efstathiou; J.J. Paly; S.D. Halpern; J.P. Christodouleas; C. Devil 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Prospective Preference Assessment of Pat

Prospective Preference Assessment of Patients' Willingness to Participate in a Randomized Controlled Trial of Intensity-Modulated Radiotherapy Versus Proton Therapy for Localized Prostate Cancer

✍ Anand Shah; Jason A. Efstathiou; Jonathan J. Paly; Scott D. Halpern; Deborah W. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 434 KB

A METHOD FOR USING LIFE TABLES TO ESTIMA

A METHOD FOR USING LIFE TABLES TO ESTIMATE LIFE-TIME RISK OF PROSTATE CANCER-DEATH IN MEN MANAGED WITHOUT CURATIVE LOCAL THERAPY

✍ Blumenfeld, Aaron J; Puymon, Marvin R; Guru, Khurshid A; Mohler, James L; Kim, H 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 93 KB

Estimating survival gain for economic ev

Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

✍ N. Neymark; I. Adriaenssen; T. Gorlia; S. Caleo; M. Bolla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

## Abstract The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival t

Commentary on “Surrogate endpoints for p

Commentary on “Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localized or locally advanced prostate cancer: An analysis of 2 randomized trials.” A.V. D'Amico, M.H. Chen, M. de Castro, M. Loffredo, D.S. Lamb, A. Steigler, P.W. Kantoff, J.W. Denham, Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA

✍ Trump, Donald L. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB